Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719745 | 0.91 | SMN1; SMN2 (0.47) | MAPTSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL718600 | 0.89 | SMN1; SMN2 (0.45) | MAPTSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL27852540 | 0.87 | SMN1; SMN2 (0.44) | MAPTSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL14905671 | 0.85 | MAPT (0.47) | MAPTSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL719678 | 0.83 | CFTR (0.41) | MAPTGAAALDH1A1KDM4ECFTR | |
| SCHEMBL719325 | 0.83 | LMNA (0.43) | MAPTSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL719337 | 0.82 | PANK3 (0.42) | MAPTSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL719795 | 0.81 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL719529 | 0.80 | LMNA (0.43) | MAPTSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL6035696 | 0.79 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015641-B | Heterocyclic compound | TAKEDA PHARMACEUTICAL | 2014-01-01 | — | — | CN | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-102015641-A | Heterocyclic compound | TAKEDA PHARMACEUTICAL | 2011-04-13 | — | — | CN | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MAPT 4533/4885SMN1; SMN2 1051/4885NPC1 902/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MAPT 4533/4885SMN1; SMN2 1051/4885NPC1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.